According to Clovis Oncology's latest financial reports the company has S$75.08 Million in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2021-12-31 | S$0.19 B | -38.99% |
2020-12-31 | S$0.31 B | -20.54% |
2019-12-31 | S$0.39 B | -43.72% |
2018-12-31 | S$0.71 B | -5.76% |
2017-12-31 | S$0.75 B | 95.72% |
2016-12-31 | S$0.38 B | -48.48% |
2015-12-31 | S$0.74 B | 17.24% |
2014-12-31 | S$0.63 B | 55.74% |
2013-12-31 | S$0.40 B | 132.4% |
2012-12-31 | S$0.17 B | -2.98% |
2011-12-31 | S$0.18 B | 532.33% |
2010-12-31 | S$28.72 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() BioMarin Pharmaceutical BMRN | S$1.63 B | 2,081.64% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | S$6.94 B | 9,150.69% | ๐ฌ๐ง UK |
![]() Pfizer PFE | S$22.29 B | 29,591.36% | ๐บ๐ธ USA |
![]() Johnson & Johnson JNJ | S$49.93 B | 66,396.91% | ๐บ๐ธ USA |
![]() AbbVie ABBV | S$6.66 B | 8,775.17% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | S$4.14 B | 5,422.46% | ๐บ๐ธ USA |